Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Globus Medical(GMED)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GMED
10/08/2026: GMED (2-star) is currently NOT-A-BUY. Pass it for now.
Globus Medical is a focused medical device company known for its spinal implants and robotic-assisted surgical platforms. The company has historically maintained strong profit margins and is recognized for its efficient product innovation and direct sales force. Its primary investment story centers on the integration of its Excelsius robotic ecosystem with a broader portfolio following the NuVasive merger. Key risks include intense competition from larger medical device peers, potential operational challenges from its large-scale acquisition, and valuation sensitivity. The stock typically suits growth-oriented investors looking for exposure to high-tech surgical trends, though those seeking dividends or low-volatility assets may find it less suitable given its growth-focused capital allocation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company targets high-growth segments in orthopedics and robotics. |
| Momentum investor | Strong fit while signal remains positive | Strong market interest in robotic-assisted surgery often drives momentum. |
| Value investor | Mixed fit | The stock often trades at a premium multiple due to its growth profile. |
| Dividend investor | Weak fit | The company does not pay a dividend. |
| Low-risk investor | Mixed fit | Healthcare volatility and integration risks may deter conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Growth-oriented medical device stocks can experience sharp price swings. |
| Valuation risk | Medium / high | Premium pricing requires sustained high growth to justify the multiple. |
| Competition risk (robotics competition) | High | Intense competition from well-capitalized players like Medtronic and Stryker. |
| Business quality | Strong | The company maintains high gross margins and proprietary technology. |
| Dividend income | Low / none | Investors seeking yield will not find it here. |
| Execution risk | Medium | Successfully integrating the NuVasive business remains a key challenge. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 20.19% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/08/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.90B USD | Price to earnings Ratio 19.61 | 1Y Target Price 100.92 |
Price to earnings Ratio 19.61 | 1Y Target Price 100.92 | ||
Volume (30-day avg) 1.5M shares | Beta 0.96 | 52 Weeks Range 56.50 - 101.40 | Updated Date 10/08/2026 |
52 Weeks Range 56.50 - 101.40 | Updated Date 10/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.76 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Spinal Implants | Hardware and fixation devices. | The bread-and-butter revenue providing recurring sales. |
| Enabling Technology | Excelsius systems and related service revenue. | The growth engine and technology differentiator. |
| Geography | US vs. International sales. | Primarily a US-centric business with growing international exposure. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 19.61 | Forward PE 13.87 | Enterprise Value 9.45B | Price to Sales(TTM) 3.15 |
Enterprise Value 9.45B | Price to Sales(TTM) 3.15 | ||
Enterprise Value to Revenue 3 | Enterprise Value to EBITDA 9.9 | Shares Outstanding 111.83M | Shares Floating 110.92M |
Shares Outstanding 111.83M | Shares Floating 110.92M | ||
Percent Insiders 0.61 | Percent Institutions 92.23 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Globus Medical
Exchange NYSE | Headquarters Audubon, PA, United States | ||
IPO Launch date 2012-08-03 | CEO, President & Director Mr. Keith W. Pfeil | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6000 | Website https://www.globusmedical.com |
Full time employees 6000 | Website https://www.globusmedical.com | ||
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.